Skip to Content
Merck
CN

G5013

G 418 disulfate salt

potency: ≥720 μg per mg (dried basis)

Synonym(s):

Antibiotic G418

Sign In to View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C20H40N4O10 · 2H2SO4
CAS Number:
108321-42-2
Molecular Weight:
692.71
MDL number:
MFCD00058314
UNSPSC Code:
51102829
PubChem Substance ID:
24895193
NACRES:
NA.85

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

form

powder

Quality Level

200

potency

≥720 μg per mg (dried basis)

color

white to off-white

solubility

H2O: 100 mg/mL

antibiotic activity spectrum

Gram-negative bacteria

Mode of action

protein synthesis | interferes

storage temp.

2-8°C

SMILES string

OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](OC[C@@]1(C)O)O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H]([C@H](C)O)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O

InChI

1S/C20H40N4O10.2H2O4S/c1-6(25)14-11(27)10(26)9(23)18(32-14)33-15-7(21)4-8(22)16(12(15)28)34-19-13(29)17(24-3)20(2,30)5-31-19;2*1-5(2,3)4/h6-19,24-30H,4-5,21-23H2,1-3H3;2*(H2,1,2,3,4)/t6?,7-,8+,9+,10+,11-,12-,13-,14+,15+,16-,17-,18+,19-,20+;;/m0../s1

InChI key

UHEPSJJJMTWUCP-NKCAIAFTSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Chemical structure: aminoglycoside

Preparation Note

G418 powder is soluble in water at 100 mg/mL.

Disclaimer

The product is stable for three years when stored at 2-8°C. Aqueous solutions stored frozen at -20 to -70 °C should be stable for approximately six months.

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H317,H334

Hazard Classifications

Resp. Sens. 1 - Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

涉药品监管产品
涉药品监管产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000504476
WXBF6612V
0000435244
0000435243
0000435243

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Triplet imaging of oxygen consumption during the contraction of a single smooth muscle cell (A7r5).
Matthias Geissbuehler et al.
Advances in experimental medicine and biology, 737, 263-268 (2012-01-20)
Yoshie Tange et al.
PLoS genetics, 8(6), e1002776-e1002776 (2012-06-28)
To identify the genes required to sustain aneuploid viability, we screened a deletion library of non-essential genes in the fission yeast Schizosaccharomyces pombe, in which most types of aneuploidy are eventually lethal to the cell. Aneuploids remain viable for a
Alexandra L Petrache et al.
Frontiers in cellular neuroscience, 14, 568194-568194 (2020-12-03)
Selective negative allosteric modulators (NAMs), targeting α5 subunit-containing GABAA receptors (GABAARs) as potential therapeutic targets for disorders associated with cognitive deficits, including Alzheimer's disease (AD), continually fail clinical trials. We investigated whether this was due to the change in the
Shijia Yu et al.
Frontiers in cellular neuroscience, 14, 193-193 (2020-08-08)
Cerebral ischemic stroke is regarded as one of the most serious diseases in the human central nervous system. The secondary ischemia and reperfusion (I/R) injury increased the difficulty of treatment. Moreover, the latent molecular regulating mechanism in I/R injury is
Frida C Mohlin et al.
Molecular immunology, 65(2), 367-376 (2015-03-04)
Atypical hemolytic uremic syndrome (aHUS) is a disease of complement dysregulation, characterized by hemolytic anemia, thrombocytopenia and acute renal failure. Mutations in complement inhibitors are major risk factors for development of aHUS. The three aHUS patients reported in this study
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service